改变治疗模式和改善复发/耐药地幔细胞淋巴瘤的治疗结果:一个前性队列研究
Allison M Bock1,2, Jennifer J Gile1, Melissa C Larson3
1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Blood cancer journal
|November 13, 2023
概括
对复发性/耐药性地幔细胞淋巴瘤 (MCL) 的治疗进展已经改善了结果. 二线治疗模式随着时间的推移而演变,显著提高了MCL患者的无事件生存率 (EFS) 和整体生存率 (OS).
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 上衣细胞淋巴瘤 (MCL) 的前线治疗在过去二十年中取得了重大进展.
- 随后的治疗线对复发性/耐药性 (R/R) MCL 的生存结果的影响仍然不太清楚.
研究的目的:
- 研究接受二线 (2L) 治疗的R/R MCL患者的不断变化的治疗模式和生存结果.
- 将不同治疗时期的结果进行比较,以评估治疗进步的影响.
主要方法:
- 2002年至2015年期间被诊断患有MCL的成年患者的前性队列研究.
- 对临床特征,2L治疗细节和结果的分析,按治疗时期 (2003-2009,2010-2014,2015-2021) 分层.
主要成果:
- 对R/RMCL的二线 (2L) 治疗是异质的,并且随着时间的推移发生了显著的转变.
- 预计无事件的2年生存率 (EFS) 分别为1,2和3期为21%,40%和51%.
- 估计的5年整体存活率分别为1,2,3期为31%,37%和67%.
结论:
- 在R/R MCL中,不断变化的2L治疗模式与改善的EFS和OS相关.
- 随后的治疗线的治疗进展与R/R MCL患者的更好的结果有关.
- 现实世界的证据支持当代2L疗法在MCL管理中的积极影响.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.4K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Bone Marrow Sampling and Transplants
339
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
339
Tumor Immunotherapy
533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
